Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

Laura W. Dillon, Sheida Hayati, Gregory W. Roloff, Ilker Tunc, Mehdi Pirooznia, Antonina Mitrofanova, and Christopher S. Hourigan

Disclosures: 1. This work was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. GWR is supported by the Medical Research Scholars Program, a public-private partnership supported jointly by the NIH, and by generous contributions to the Foundation for the NIH by the Doris Duke Charitable Foundation (Grant #2014194). 2. CSH receives research funding from Merck Sharpe & Dohme and SELLAS Life Sciences Group AG. The other authors declare no conflicts of interest. 3. Nothing to disclose.

Contributions: LWD designed and performed research, analyzed and interpreted data, and wrote the manuscript. SH developed bioinformatics pipeline, analyzed and interpreted data, and aided in research design. GWR designed and performed research. IT, MP, and AM analyzed and interpreted data. CSH designed research, analyzed and interpreted data, and wrote the manuscript.